Skip to main content Back to Top


Ethambutol Tablets

Products Affected - Description

    • Myambutol tablet, X-Gen, 100 mg, 100 count, NDC 68850-0010-01
    • Ethambutol tablet, Teva, 400 mg, 100 count, NDC 00555-0923-02

Reason for the Shortage

    • Akorn is currently only marketing ethambutol 100 mg and 400 mg tablets in 100 count size. All other presentations are not being marketed.
    • Teva has had ethambutol tablets unavailable since 2013.
    • X-Gen discontinued ethambutol 100 mg tablets in early-2015.

Available Products

    • Myambutol tablet, X-Gen, 400 mg, 100 count, NDC 68850-0012-02
    • Myambutol tablet, X-Gen, 400 mg, 100 count, NDC 68850-0012-01
    • Ethambutol tablet, Akorn, 100 mg, 100 count, NDC 61748-0011-01
    • Ethambutol tablet, Akorn, 400 mg, 100 count, NDC 61748-0014-01
    • Ethambutol tablet, Lupin, 100 mg, 100 count, NDC 68180-0280-01
    • Ethambutol tablet, Lupin, 400 mg, 100 count, NDC 68180-0281-01

Estimated Resupply Dates

    • All marketed presentations are currently available.


Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 6, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins